LX-1

N/A

Report date: 2025/01/26 15:32:58

NME

Base Information

Drug NameLX-1

Drug Alias Namedual AKR1C3 and AR/AR-V7 inhibitor (University of California Davis)dual aldo-keto reductase 1C3 inhibitor/androgen receptor inhibitor (University of California Davis)LX-1

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAndrogen Receptor degradersAldo-keto-reductase family 1 member C3 inhibitors

TargetsAldo-keto-reductase family 1 member C3Androgen Receptor

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of California Davis

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California Davis

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A